
IndraLab
Statements
sparser
"We observed a slight increase in SPRTN-USP11 interaction following treatment with etoposide (VP16), a TOP2 crosslinking agent ( xref D , xref ), camptothecin (CPT), TOP1 cross-linking agent, formaldehyde (nonspecific cross-linking agent), and hydroxyurea (non-cross-linking agent) ( xref )."
sparser
"Co-immunoprecipitation (Co-IP) of Myc-USP11 with SFB-SPRTN full-length (FL) or ΔSprT, ΔSH, ΔPIP, ΔUBZ, E112A catalytic inactive, and Y117C (SPRTN mutation identified in RJALS patients) mutant constructs showed that SPRTN-USP11 interaction was lost with deletion of the N-terminal SprT domain of SPRTN ( xref A )."